Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles

International Journal of Pharmaceutics

Volumn 415, Issue 1-2, 2011, Pages 244-251

  Wohlfart, Stefanie ^a   Khalansky, Alexander S ^b   Bernreuther, Christian ^c   Michaelis, Martin ^d   Cinatl, Jindrich ^d   Glatzel, Markus ^c   Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

^b RESEARCH INSTITUTE OF HUMAN MORPHOLOGY   (Russian Federation)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Doxorubicin; Glioblastoma; Histology; Nanoparticles; Poly(isohexyl cyanoacrylate)

Indexed keywords

DOXORUBICIN; GLIAL FIBRILLARY ACIDIC PROTEIN; NANOPARTICLE; POLY(ISOHEXYLCYANOACRYLATE); POLYSORBATE 80; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; ELECTRON MICROSCOPY; GLIOBLASTOMA; HISTOPATHOLOGY; IC 50; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURFACE CHARGE; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYANOACRYLATES; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY; SURFACE PROPERTIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960193278     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.05.046     Document Type: Article

References (36)

1. F.G. Barker II, R.L. Davis, S.M. Chang, and M.D. Prados Necrosis as a prognostic factor in glioblastoma multiforme Cancer 77 1996 1161 1166 (Pubitemid 26080909)
2. L. Barraud, P. Merle, E. Soma, L. Lefrancois, S. Guerret, M. Chevallier, C. Dubernet, P. Couvreur, C. Trepo, and L. Vitvitski Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo J. Hepatol. 42 2005 736 743
3. A. Behin, K. Hoang-Xuan, A.F. Carpentier, and J.Y. Delattre Primary brain tumours in adults Lancet 361 2003 323 331 (Pubitemid 36126198)
4. E. Configliacchi, G. Razzano, V. Rizzo, and A. Vigevani HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates J. Pharm. Biomed. Anal. 15 1996 123 129 (Pubitemid 26323637)
5. C. Cuvier, L. Roblot-Treupel, J.M. Millot, G. Lizard, S. Chevillard, M. Manfait, P. Couvreur, and M.F. Poupon Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance Biochem. Pharmacol. 44 1992 509 517
6. N.D. Doolittle, L.E. Abrey, W.A. Bleyer, S. Brem, T.P. Davis, P. Dore-Duffy, L.R. Drewes, W.A. Hall, J.M. Hoffman, A. Korfel, R. Martuza, L.L. Muldoon, D. Peereboom, D.R. Peterson, S.D. Rabkin, Q. Smith, G.H. Stevens, and E.A. Neuwelt New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual blood-brain barrier disruption consortium meeting Clin. Cancer Res. 11 2005 421 428 (Pubitemid 40116864)
7. S.J. Douglas, L. Illum, S.S. Davis, and J. Kreuter Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles: I. Influence of physicochemical factors J. Colloid.Interface Sci. 101 1984 149 158 (Pubitemid 14642183)
8. E.M. Gipps, P. Groscurth, J. Kreuter, and P. Speiser The effects of polyalkylcyanoacrylate nanoparticles on human normal and malignant cells in vitro Int. J. Pharm. 40 1987 23 31
9. V. Guise, P. Jaffray, J. Delattre, F. Puisieux, M. Adolphe, and P. Couvreur Comparative cell uptake of propidium iodide associated with liposomes or nanoparticles Cell. Mol. Biol. 33 1987 397 405
10. T. Hekmatara, C. Bernreuther, A.S. Khalansky, A. Theisen, J. Weissenberger, J. Matschke, S. Gelperina, J. Kreuter, and M. Glatzel Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects Clin. Neuropathol. 28 2009 153 164
11. C.S. Jung, C. Foerch, A. Schanzer, A. Heck, K.H. Plate, V. Seifert, H. Steinmetz, A. Raabe, and M. Sitzer Serum GFAP is a diagnostic marker for glioblastoma multiforme Brain 130 2007 3336 3341 (Pubitemid 350209077)
12. J. Kattan, J.P. Droz, P. Couvreur, J.P. Marino, A. Boutan-Laroze, P. Rougier, P. Brault, H. Vranckx, J.M. Grognet, and X. Morge Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles Invest. New Drugs 10 1992 191 199
13. K. Kostarelos Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science Adv. Colloid Interface Sci. 106 2003 147 168
14. J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R. Alyautdin, H. von Briesen, and D.J. Begley Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm. Res. 20 2003 409 416 (Pubitemid 36288370)
15. J. Kufleitner, S. Wagner, F. Worek, H. von Briesen, and J. Kreuter Adsorption of obidoxime onto human serum albumin nanoparticles: Drug loading, particle size and drug release J. Microencapsul. 27 2010 506 513
16. K. Langer, E. Seegmüller, A. Zimmer, and J. Kreuter Characterisation of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans Int. J. Pharm. 110 1994 21 27
17. C. Lherm, R.H. Müller, F. Puisieux, and P. Couvreur Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length Int. J. Pharm. 84 1992 13 22
18. D.N. Louis Molecular pathology of malignant gliomas Annu. Rev. Pathol. 1 2006 97 117
19. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, A. Jouvet, B.W. Scheithauer, and P. Kleihues The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol. 114 2007 97 109 (Pubitemid 47103521)
20. P. Merle, S. Si Ahmed, F. Habersetzer, A. Abergel, J. Taieb, L. Bonyhay, D. Constantini, J. Dufour-Lamartinie, and C. Trepo Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC) J. Clin. Oncol. 2006 24, 18S, 14094
21. M. Michaelis, U.R. Michaelis, I. Fleming, T. Suhan, J. Cinatl, R.A. Blaheta, K. Hoffmann, R. Kotchetkov, R. Busse, H. Nau, and J. Cinatl Jr. Valproic acid inhibits angiogenesis in vitro and in vivo Mol. Pharmacol. 65 2004 520 527 (Pubitemid 38264019)
22. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
23. R.H. Muller, C. Lherm, J. Herbort, and P. Couvreur In vitro model for the degradation of alkylcyanoacrylate nanoparticles Biomaterials 11 1990 590 595 (Pubitemid 20367837)
24. E. Pereverzeva, I. Treschalin, D. Bodyagin, O. Maksimenko, J. Kreuter, and S. Gelperina Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats Toxicol. Lett. 178 2008 9 19
25. E. Pereverzeva, I. Treschalin, D. Bodyagin, O. Maksimenko, K. Langer, S. Dreis, B. Asmussen, J. Kreuter, and S. Gelperina Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity Int. J. Pharm. 337 2007 346 356 (Pubitemid 46756061)
26. B. Petri, A. Bootz, A. Khalansky, T. Hekmatara, R. Muller, R. Uhl, J. Kreuter, and S. Gelperina Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants J. Controll Release 117 2007 51 58 (Pubitemid 46164866)
27. G. Schoch, H. Seeger, J. Bogousslavsky, M. Tolnay, R.C. Janzer, A. Aguzzi, and M. Glatzel Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease PLoS Med. 3 2006 e14
28. S.C. Steiniger, J. Kreuter, A.S. Khalansky, I.N. Skidan, A.I. Bobruskin, Z.S. Smirnova, S.E. Severin, R. Uhl, M. Kock, K.D. Geiger, and S.E. Gelperina Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles Int. J. Cancer 109 2004 759 767 (Pubitemid 38405625)
29. T.R. Tice, and D.R. Cowsar Biodegradable controlled-release parernteral systems Pharm. Technol. 11 1984 26 36
30. C. Vauthier, C. Dubernet, C. Chauvierre, I. Brigger, and P. Couvreur Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles J. Control Release 93 2003 151 160 (Pubitemid 37421357)
31. W. Wick, J. Tonn, and M. Weller Primäre intrakranielle und spinale Tumoren T. Brandt, J. Dichgans, H.C. Diener, Therapie und Verlauf Neurologischer Erkrankungen 5th Ed. 2007 Kohlhammer Stuttgart 832 867
32. S. Wohlfart, C. Bernreuther, A. Khalansky, A. Theisen, J. Weissenberger, S. Gelperina, M. Glatzel, and J. Kreuter Increased numbers of injections of doxorubicin bound to nanoparticles lead to enhanced efficacy against rat glioblastoma 101/8 J. Nanoneurosci. 1 2009 144 151
33. S. Wohlfart, A. Khalansky, S. Gelperina, O. Maksimenko, C. Bernreuther, M. Glatzel, and J. Kreuter Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded plga nanoparticles with different stabilizers PloS ONE 6 2011 e19121
34. L.Y. Yablonovskaya, and A.P. Avtsyn Malignant glioma induced in rabbits by methylcholanthrene Fed. Proc. Transl. Suppl. 23 1964 1047 1050
35. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, C. Buchel, and J. Kreuter Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain J. Drug Target 18 2010 842 848
36. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Buchel, H. von Briesen, and J. Kreuter Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones J. Control Release 137 2009 78 86